{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:14:06Z","timestamp":1790007246778,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Hemophilia B is a rare X-chromosome linked hereditary bleeding disorder. Patients require lifelong treatment and it is costly, but there is a lack of research in China on the treatment and burden for this group. Our aim was to review the actual treatment pattern of hemophilia B patients in China, and describe the financial burden and other disease burden from the patient\u2019s perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using data collected by the Beijing Hemophilia Home Care Center, descriptive statistics were made on the sociodemographic characteristics and treatment of patients. The annual drug costs were calculated according to the actual factor dosage and price.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the study period, 29.9% of the patients only received on-demand treatment, while the rest of the patients received varying numbers of prophylaxis treatment. The total cost of clotting factors for 341 patients in one year was 16.0 million CNY ($2.5 million), with 46990.8 CNY ($7283.7) per patient. The drug cost of prophylaxis was significantly higher than that of on-demand treatment. The amount of prothrombin complex concentrates used by patients was the largest, more than 5 times of recombinant coagulation factor IX. Based on the average annual wage and average working time of Chinese employees in 2021, the average annual wage loss of HB patients reached 31544.2 CNY ($4889.4). The results of the questionnaire showed that 77.1% and 65.3% of patients had chronic pain and acute pain of different frequencies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The level of prophylaxis for Chinese patients is low; safer and more effective recombinant drugs are not widely available. Patients also face a high burden of drug costs, as well as indirect costs that cannot be underestimated. Therefore, continued efforts are needed to improve the quality of life of patients by reducing their financial burden and promote standardized treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1303787","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:13:46Z","timestamp":1706069626000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Current status of treatment and disease burden of a cohort of hemophilia B in China"],"prefix":"10.3389","volume":"11","author":[{"given":"Yiwen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuchuan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3760\/cma.j.issn.0253-2727.2017.05.002","article-title":"Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)","volume":"38","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref2","first-page":"15","volume-title":"Gazette of the National Health Commission of People's Republic of China","year":"2018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2013from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"ref4","first-page":"455","article-title":"The prevalence of hemophilia in mainland China: a systematic review and meta-analysis","volume":"45","author":"Qu","year":"2014","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"ref5","first-page":"265","article-title":"Chinese guidelines on the treatment of hemophilia(version 2020)","year":"2020","journal-title":"Chin J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"107602961988802","DOI":"10.1177\/1076029619888023","article-title":"Differences in major bleeding events between patients with severe hemophilia a and hemophilia B: a Nationwide, population-based cohort study","volume":"25","author":"Shih","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref7","first-page":"49","article-title":"Consensus of Chinese expert on the diagnosis and treatment of hemophilia","volume":"23","author":"Ding","year":"2010","journal-title":"J Clin Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/hae.14278","article-title":"Evidence of a disability paradox in patient-reported outcomes in haemophilia","volume":"27","author":"O\u2019Hara","year":"2021","journal-title":"Haemophilia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1055\/s-0035-1564801","article-title":"Current issues in hemophilia: recognizing clinical heterogeneity, replacement therapy, and outcome assessment preface","volume":"41","author":"Srivastava","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13023-021-01774-9","article-title":"Clinical, humanistic, and economic burden of severe hemophilia B in the United States: results from the CHESS US and CHESS US+ population surveys","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","article-title":"Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12913-022-07626-x","article-title":"Medical costs and hospital utilization for hemophilia a and B urban inpatients in China: a national cross-sectional study","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-020-01423-7","article-title":"Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015","volume":"15","author":"Gong","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/hae.14029","article-title":"Real-world analysis of haemophilia patients in China: a single centre's experience","volume":"26","author":"Song","year":"2020","journal-title":"Haemophilia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/16078454.2020.1741205","article-title":"Economic burden of hemophilia a and B: a case in Iran","volume":"25","author":"Keshavarz","year":"2020","journal-title":"Hematology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","article-title":"Health care resource utilization and cost burden of hemophilia bin the United States","volume":"5","author":"Buckner","year":"2021","journal-title":"Blood Adv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.transci.2016.01.025","article-title":"Health care resource utilization and cost of care for haemophilia a and B patients in Iran","volume":"54","author":"Gharibnaseri","year":"2016","journal-title":"Transfus Apher Sci"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1303787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:13:52Z","timestamp":1706069632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1303787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":21,"alternative-id":["10.3389\/fpubh.2023.1303787"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1303787","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"article-number":"1303787"}}